1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
Global Drug-Eluting Stents Market

Global Drug-Eluting Stents Market

  • November 2020
  • 127 pages
  • ID: 5983281
  • Format: PDF
  • BCC Research

Summary

Table of Contents

Report Scope:
This report examines the current and projected market potential of drug-eluting stents.It offers a detailed analysis of the regulatory scenario, competitive environment, pipeline, technological advancement, drivers, restraints and market growth trends.

The report also includes market projections through 2024 and the market rank for key market players. The report details the market share of drug-eluting stents based on types of product, application and end user.

By product type, the market is segmented into polymer-based drug-eluting stents and polymer-free drug-eluting stents.By application, the market is segmented into coronary artery disease (CAD) and peripheral artery disease (PAD).

By end user, the market is segmented into hospitals, ambulatory surgical centers and specialty centers and clinics.

By geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data is provided for 2018 as the base year, 2019 and forecast through year-end 2024. Estimated values used are based on drug-eluting stent manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:
- 20 data tables and 18 additional tables
- An overview of global market for drug-eluting stents within the medical devices industry
- Estimation of the market size and analyses of market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Market share analysis of the drug-eluting stents based on product, application, end-use, and region
- Identification of segments with high growth potential and analysis of future applications of each of the segments
- Assessment of market dynamics for drug-eluting stents with market drivers and restraints explained, medical device regulations, market background and pipeline analysis of the stents
- Coverage of prevalence and epidemiology of cardiovascular disease and description of coronary artery disease (CAD) and peripheral artery disease (PAD)
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of the leading market players, including Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corp., Medtronic Plc and Cook Medical Inc.

Summary:
The global market for drug-eluting stents was valued at REDACTED in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach REDACTED by 2024.

Global market growth is attributed to the growing prevalence of cardiovascular diseases, a rise in the world’s geriatricpopulation and a growing demand for minimally invasive procedures.

There has been remarkable growth in the development of coronary stents to avoid restenosis and thrombosis.Improvements include progress in the design and conformation of metallic or resorbable structures, with an adequate balance between trackability and radial force.

Also noted is the development of antiproliferative drugs and polymers to control release and allow adequate endothelialization and optimal duration of the antiplatelet regimen.These developments led to growth in the drug-eluting stent market over the forecast period.

DES use rates escalated rapidly, quickly reaching about REDACTED of total stent use in the U.S. and some European countries.

Drug-eluting stents are coated with a drug and polymer, designed to allow for controlled and consistent release of the drug from the stent surface into the artery walls. Both the amount of drug and release rate has been determined so that healing can occur while allowing the processes leading to restenosis to be minimized, reducing the need for additional treatment in the stented area.

Rising incidence of CVD, heart failure and coronary heart disease cases come with growing prevalence of obesity, diabetes and high blood pressure, globally.These phenomena are anticipated to fuel drugeluting stents market growth over the forecast period.

According to the WHO, in 2016, an estimated REDACTED people died from CVD, signifying REDACTED of all global deaths.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on